Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company

Exact Sciences与Genomic Health正式合并,打造全球领先的癌症诊断公司

2019-11-29 14:23:07 BioSpace

本文共2307个字,阅读需6分钟

Combined company joins two leading brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth Exact Sciences Corp. (NASDAQ: EXAS) today announced that it has completed its previously announced combination with Genomic Health, Inc. (NASDAQ: GHDX). "Today marks a pivotal step toward building the world's leading advanced cancer diagnostics company," said Kevin Conroy, chairman and CEO of Exact Sciences. "We're excited to bring together some of the greatest minds in cancer diagnostics and continue to deliver advanced tests to providers and patients along their cancer journey. With a best-in-class R&D, clinical, and commercial organization and a global infrastructure, we are well positioned to increase adoption of our existing tests and accelerate the development and launch of future cancer diagnostics. I welcome the talented Genomic Health employees to the Exact Sciences family and look forward to leading our combined team as we enter our Company's next chapter." As a result of the transaction's close, Genomic Health's common stock will now cease to be traded on the NASDAQ. Contacts Investor Relations: Megan Jones meganjones@exactsciences.com 608-535-8815 Media: Cara Connelly cconnelly@exactsciences.com 614-302-5622 About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Fueled by the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Alongside its visionary collaborators and in partnership with communities, Exact Sciences unites the best resources to help advance the fight against cancer. For more information, please visit the company's website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook. Forward-Looking Statements This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this news release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales, marketing and patient adherence efforts, expectations concerning payer reimbursement, the anticipated results of our product development efforts and the anticipated benefits of our acquisition of Genomic Health, including estimated synergies and other financial impacts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payers to cover our products and services and adequately reimburse us for such products and services; the amount and nature of competition from other cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any law, rule, order, interpretation or policy relating to the healthcare system, including without limitation as a result of any judicial, executive or legislative action; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services and assess potential market opportunities; our ability to effectively utilize strategic partnerships, such as through our Promotion Agreement with Pfizer, Inc., and acquisitions; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; expectations regarding our international expansion and opportunities; the potential effects of foreign currency exchange rate fluctuations and our efforts to hedge such effects; the possibility that the anticipated benefits from our acquisition of Genomic Health cannot be realized in full or at all or may take longer to realize than expected; the possibility that costs or difficulties related to the integration of Genomic Health's operations will be greater than expected; the outcome of any litigation, government investigations, enforcement actions or other legal proceedings; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. multimedia:http://www.prnewswire.com/news-releases/exact-sciences-completes-combination-with-genomic-health-creating-leading-global-cancer-diagnostics-company-300954724.html
联合公司加入了癌症诊断领域的两大领先品牌 Cologuard ®和 Oncotype DX ®,为持续增长提供了强大的平台 Exact Sciences Corp .( NASDAQ : EXAS )今天宣布,已完成先前宣布的与 Genomic Health , Inc .( NASDAQ : GHDX )合并。 “今天标志着建立世界领先的先进癌症诊断公司的关键一步,” Exact Sciences 董事长兼首席执行官凯文·康罗伊说。“我们很高兴将癌症诊断领域的一些最伟大的思想汇聚在一起,并在癌症过程中继续为提供者和患者提供先进的测试。凭借一流的研发、临床、商业组织和全球基础设施,我们处于有利地位,能够增加现有试验的采用,加快未来癌症诊断的开发和推出。我欢迎有才华的基因健康员工加入 Exact Sciences 大家庭,并期待在我们进入公司下一章的时候领导我们的联合团队。 由于交易结束, Genomic Health 的普通股将不再在纳斯达克交易。 联系人 投资者关系: 梅根·琼斯 meganjeones @ exactsciences.com 608-535-8815 媒体: Cara Connelly cconnelly @ exactsciences.com 614-302-5622 关于精密科学公司。 作为一家领先的癌症筛查和诊断测试的供应商,精密科学公司不遗余力地追求更聪明的解决方案,从而更早地采取改变生命的行动。在 Cologuard 和 Oncotype DX 成功的推动下, Exact Sciences 正在投资其产品管道,以应对一些最致命的癌症并改善病人护理。除了有远见的合作者和与社区合作,精密科学联合最好的资源,以帮助推进对抗癌症的斗争。有关更多信息,请访问公司网站 www.exactsciences.com ,在 Twitter @ ExactSciences 上跟踪 Exact Sciences ,或在 Facebook 上找到 Exact Sciences 。 前瞻性陈述 本新闻稿载有经修订的《1933年证券法》第27A 条和经修订的《1934年证券交易法》第21E 条含义内的前瞻性陈述,旨在涵盖这些章节创建的“安全港”。前瞻性陈述基于一定的假设并描述我们未来的计划、战略和预期,通常可以通过使用前瞻性的术语如“相信”、“预期”、“可能”、“会”、“应该”、“会”、“可以”、“寻求”、“打算”、“计划”、“目标”、“项目”、“估计”来识别。“预期”或其他类似术语。除了本新闻稿所载有关我们的战略、前景、财务状况、营运、成本、计划及目标的历史事实陈述外,所有其他陈述均为前瞻性陈述。前瞻性陈述的例子包括,除其他外,我们就预期未来经营业绩、我们的销售预期结果、市场营销和患者依从性努力、有关付款人偿付的预期我们产品开发工作的预期结果和收购 Genomic Health 的预期收益,包括估计的协同效应和其他财务影响。前瞻性陈述既不是历史事实,也不是对未来业绩的保证。相反,它们仅基于我们目前对业务未来、未来计划和战略、预测、预期事件和趋势、经济和其他未来条件的信念、预期和假设。由于前瞻性陈述与未来相关,因此它们受到难以预测的内在不确定性、风险和情况变化的影响,其中许多不在我们的控制范围之内。我们的实际业绩及财务状况可能与前瞻性陈述所示有重大差异。因此,你不应依赖任何这些前瞻性陈述。可能导致我们的实际业绩及财务状况与前瞻性陈述所示有重大差异的重要因素包括(其中包括)以下方面:我们成功及盈利地销售产品及服务的能力;病人及医疗服务提供者接纳我们的产品及服务;我们满足产品及服务需求的能力;健康保险公司及其他缴纳人愿意支付我们的产品及服务,并就该等产品及服务向我们作出适当补偿;其他癌症筛查及诊断产品及服务的竞争金额及性质;采纳、修订或废除任何与医疗保健系统有关的法律、规则、命令、诠释或政策的影响,包括但不限于因任何司法、行政或立法行动而产生的影响;我们产品及服务的定价、覆盖率及偿还费用的变动影响;包括但不限于2014年《保护获得医疗保险法案》的结果;美国预防服务工作组、美国癌症学会(American Cancer Society)以及关于癌症筛查或我们的产品和服务的国家质量保证委员会;我们成功开发新产品和服务并评估潜在市场机会的能力;我们有效利用战略伙伴关系的能力,例如通过我们与辉瑞(Pfizer)公司的推广协议和收购;我们成功地建立并保持协作,许可和供应商安排;我们保持监管批准和遵守适用法规的能力;对我们的国际扩张和机会的预期;外汇汇率波动的潜在影响和我们为对冲这些影响所做的努力;我们收购基因组健康的预期收益不能全部或全部实现或可能需要比预期更长的时间实现的可能性;与基因组健康业务整合相关的成本或困难大于预期的可能性;任何诉讼、政府调查的结果,强制执行诉讼或其他法律程序;以及风险因素和管理层对财务状况和经营业绩讨论与分析中描述的其他风险和不确定性。我们最近提交的10-K报表年度报告和随后提交的10-Q 季度报告中的运营部分。我们不承担任何义务公开更新任何可能因新信息、未来发展或其他原因而不时作出的书面或口头的前瞻性声明。 多媒体: http://www.prnewswire.com/news-releases/finger-sciences-complete-with-genetics-health-create-original-global-cancer-Diagnostics-company-300954724。html

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文